Cure8 research brief
Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.
Adult patients with refractory Crohn's disease or ulcerative colitis, clinicians prescribing JAK inhibitors, and researchers interested in real-world effectiveness and safety.
This study followed patients with Crohn's disease, ulcerative colitis, and related colitis who started upadacitinib after prior advanced therapies. Most patients (80.5%) remained on the drug during follow-up; one-year clinical remission and corticosteroid-free remission rates were reported.
Endoscopic remission rates were measured in subsets of patients who underwent endoscopy. Infections and acne were the most frequently reported adverse events. The study is observational and reflects a refractory, heavily pretreated population; outcomes may differ from regulatory trial populations.
The findings describe associations (for example, factors linked with earlier discontinuation) rather than proven causes.
This is an observational cohort reported in a journal abstract/full-text; results reflect a heavily pretreated population and are subject to limitations of nonrandomized studies (selection bias, variable follow-up, and incomplete endoscopic data).
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
This study gives real-world 52‑week data on upadacitinib maintenance in children with refractory Crohn's disease, showing meaningful remission rates but also notable adverse events. That balance is important for families...
